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Parkinson’s disease is a neurodegenerative disorder characterised by nigrostriatal dopaminergic 
degeneration, and intracellular -synuclein aggregation. Current pharmacological treatments are 
solely symptomatic so there is a need to identify agents that can slow or stop dopaminergic 
degeneration. One proposed class of therapeutics are neurotrophic factors which promote the 
survival of nigrostriatal dopaminergic neurons. However, neurotrophic factors need to be delivered 
directly to the brain. An alternative approach may be to identify pharmacological agents which can 
reach the brain to stimulate neurotrophic factor expression and/or their signalling pathways in 
dopaminergic neurons. BMP2 is a neurotrophic factor that is expressed in the human substantia 
nigra; exogenous BMP2 administration protects against dopaminergic degeneration in in vitro 
models of PD. In this study, we investigated the neurotrophic potential of two FDA-approved 
drugs, Quinacrine and Niclosamide, that are modulators of BMP2 signalling. We report that 
Quinacrine and Niclosamide, like BMP2, significantly increased neurite length, as a readout of 
neurotrophic action, in SH-SY5Y cells and dopaminergic neurons in primary cultures of rat ventral 
mesencephalon. We also show that these effects of Quinacrine and Niclosamide require the 
activation of BMP-Smad signalling. Finally, we demonstrate that Quinacrine and Niclosamide are 
neuroprotective against degeneration induced by the neurotoxins, MPP+ and 6-OHDA, and by 
viral-mediated overexpression of  -synuclein in vitro. Collectively this study identifies two drugs, 
that are safe for use in patients, that exert neurotrophic effects on dopaminergic neurons through 
modulation of BMP-Smad signalling. This rationalises the further study of drugs that target the 
BMP-Smad pathway as potential neuroprotective pharmacotherapy for Parkinson’s disease.  
 








Parkinson’s disease (PD) is a common neurodegenerative disorder characterised by the 
progressive degeneration of midbrain dopaminergic neurons and their axons, with the accumulation 
of intracellular aggregates of α-synuclein in Lewy bodies and Lewy neurites [1]. In recent years 
there has been considerable interest in developing neurotrophic factor therapy for PD. This involves 
the delivery of neurotrophic factor genes, or recombinant proteins, to the midbrain or striatum to 
protect midbrain dopaminergic neurons and their axons from degeneration [2-4]. Despite initial 
success in pre-clinical models and in open label trials [5-11], randomised controlled trials of two 
dopaminergic neurotrophic factors, glial cell line-derived neurotrophic factor (GDNF) and 
neurturin, have failed to meet their primary end-points [12-17]. Thus, there has been increasing 
interest in identifying other neurotrophic factors that are capable of protecting dopaminergic 
neurons from degeneration. The challenge surrounding neurotrophic factor therapy however, is that 
these proteins require direct administration to the brain, as they are rapidly metabolised in vivo and 
are unable to cross the blood brain barrier in adequate doses [18]. One proposed strategy to 
overcome this problem may be the identification of small molecule drugs or biologics that are 
capable of crossing the blood brain barrier and can selectively activate the receptors or downstream 
targets that mediate the action of specific neurotrophic factors. 
 
Bone morphogenetic proteins (BMPs) are a group of neurotrophic factors that, like GDNF 
and neurturin, are members of the transforming growth factor (TGF)-β superfamily (for review see 
[18, 19]). We have recently shown using gene co-expression analysis of the human substantia nigra 
(SN) that the BMP receptors (BMPRs) and BMP2 ligand have correlated patterns of expression 
with multiple markers of dopaminergic neurons in the human SN, indicating a potential functional 
role for BMP-Smad signalling in dopaminergic neuron biology [20]. Moreover, we reported that 
recombinant human (rh)BMP2 promoted neurite growth, as a single cell readout of neurotrophic 




hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+), and in cells 
overexpressing α-synuclein [20]. These data suggest that clinically-approved drugs that modulate 
BMP2 expression and/or the BMP2 signalling pathway, may be a novel class of compounds for 
protecting dopaminergic neurons in PD. 
 
In a recent study, Ghebes et al. carried out a screen of 1280 commercially available FDA-
approved compounds in primary human tendon–derived cells to identify those capable of 
modulating the BMP2 signalling pathway, which is also important for local tendon and ligament 
repair [21].  In studies using a BMP reporter cell line, they reported that two drugs, Niclosamide 
and Quinacrine, modulated the BMP2 pathway [21].  Niclosamide is an anthelmintic agent that has 
been used clinically to treat tape worm infections [22], while Quinacrine has a long history of 
clinical use in the treatment of malaria [23]. Given that Niclosamide and Quinacrine were found to 
modulate BMP2 signalling in primary tendon cells [21], and as rhBMP2 protects dopamine neurons 
in primary cultures of rat ventral mesencephalon (VM) from neurotoxin- and α-synuclein-induced 
degeneration [20], we hypothesised that these two drugs may protect against neurotoxin- and α-














Materials and Methods 
Cell culture  
Human SH-SY5Y cells (ATCC; CRL-2266) and embryonic day (E) 14 rat VM cells were cultured 
as previously described [20, 24], under license with full ethical approval. Briefly, SH-SY5Y cells 
were maintained in Dulbecco's Modified Eagle Medium F-12 (DMEM/F-12), supplemented with 
10% foetal calf serum (FCS), 100nM L-Glutamine, 100U/ml Penicillin, 10μg/ml Streptomycin (all 
from Sigma). E14 VM cells were cultured in DMEM/F-12 containing 100nM L-Glutamine, 
6mg/ml D-Glucose, 100 U/ml Penicillin, 10μg/ml Streptomycin, with 2% B-27 supplement, and 
1% FCS. All cell cultures were maintained at 37ºC and 5% CO2 for the duration of the experiment. 
Where indicated, cultures were treated with 5µl dH20 (Vehicle), 0-10nM Niclosamide (Sigma) or 
Quinacrine (Sigma), 0-200ng/ml rhBMP2 (Gibco), 5µM 6-OHDA (Sigma) or 5µM MPP+ (Sigma) 
at varying times depending on the experiment and as indicated in the figure legends. Where 
specified, cells were pre-treated with 1µg/ml dorsomorphin (Sigma), a small molecular inhibitor 
of BMP-Smad signalling [25] for 30 min prior to the addition of rhBMP2, Niclosamide or 
Quinacrine. 
ELISA for total and phosphorylated-Smad 1  
Activation of the phosphorylated-Smad (phospho-Smad) pathway by rhBMP2 was examined using 
the SMAD1 (Total/Phospho) Human InstantOne™ ELISA Kit (Invitrogen). In brief, SH-SY5Y 
cells were plated at a density of 5.0×104 cells per well of a 24-well plate and treated with or without 
1µg/ml dorsomorphin for 30 min prior to the addition of 50ng/ml rhBMP2 for 2 h. Cells were then 
lysed and protein extracts were prepared for the ELISA as per the manufacturer’s instructions.  
Transfection of SH-SY5Y cells  
SH-SY5Y cells were transfected using the TransIT-X2® Dynamic Delivery System (Mirus Bio) 
according to the manufacturer’s instructions. Briefly, SH-SY5Y cells were plated at a density of 
5.0×104 cells per well of a 24-well plate. The TransIT-X2:DNA complex was prepared according 




the Smad Binding Element (SBE)-green fluorescent protein (GFP) reporter (Qiagen) before being 
added to the wells as per the manufacturer’s instructions. 
Virus Preparation  
An α-synuclein and GFP expression plasmid were generously donated by Dr Eilis Dowd (National 
University of Ireland, Galway) and Professor Deniz Kirik (Lund University, Sweden). Adeno 
associated viral (AAV) vectors were then constructed by Vector Biosystems Inc, Philadelphia, 
USA.  Briefly, AAV2 inverted terminal repeats that coded for the human wild‐type α-synuclein or 
GFP were packaged using AAV6 capsid proteins producing AAV2/6 viral vectors. Transgene 
expression was driven by a synapsin‐1 promoter and enhanced using a woodchuck hepatitis virus 
post‐transcriptional regulatory element (WPRE). The final viral titres for AAV2/6-α-synuclein 
(AAV-αSyn) and AAV2/6-GFP (AAV-GFP) were 5.2x1013gc/ml and 5.0x1013gc/ml respectively. 
Transduction of E14 VM cultures 
E14 VM cultures were plated at a density of 1.0×105 per well of a 24-well plate and transduced 
with AAV-GFP or AAV-αSyn to achieve a multiplicity of infection (MOI) of 2.0×105. Cultures 
were then treated daily with 10nM Quinacrine or 10nM Niclosamide that commenced either at the 
time of infection (combined treatment) or treatment commenced 5 days after viral infection 
(delayed treatment). In both cases the experimental end point was at 10 days in vitro (DIV).  
Immunocytochemistry  
SH-SY5Y cells or E14 VM cultures were fixed in 4% paraformaldehyde (PFA) and processed for 
immunocytochemistry as previously described [20]. Where indicated, cells were incubated for 16 
h at 4°C in the following antibodies: tyrosine hydroxylase (TH) (1:2000, Merck Millipore), 
phospho-Smad 1/5/8 (1:200; Cell Signalling) and α-synuclein (1:2000, Merck Millipore) and 
diluted in 1% bovine serum albumin (BSA) in 10mM phosphate-buffered saline (PBS). Following 
3 × 5 min washes in PBS with Triton X-100 (PBS-T), cells were incubated in the appropriate Alexa 
Fluor 488- or 594- conjugated secondary antibodies (1:500; Invitrogen) diluted in 1% BSA in 




were counterstained with DAPI (1:3000; in 10 mM PBS; Sigma) and imaged using an Olympus 
IX71 microscope.  
Analysis of cellular morphology and nuclear intensity 
To assess cellular morphology or nuclear staining intensity, 5 randomly-selected cells were 
measured in no less than 15 randomly-selected fields per N, yielding at least 225 neurites or cell 
bodies analysed per experiment. To verify the number of TH positive (TH+) cells and total cells, 
TH and DAPI counts were completed in 15 randomly-selected fields and the numbers of TH+ cells 
were expressed as percentages of the total DAPI-stained cells. For experiments involving AAV 
vectors, 5 randomly-selected cells were measured in no less than 6 randomly-selected fields per N, 
yielding at least 90 neurites or cell bodies analysed per experiment. To verify the number of TH+ 
cells and total cells, TH and DAPI counts were completed in 6 randomly-selected fields and the 
numbers of TH+ cells were expressed as percentages of the total DAPI-stained cells. All 
experiments were repeated at least 3 times and all analyses were performed using Image J software.  
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 8 (©2020 GraphPad Software, CA USA).  
A one-way or two-way ANOVA with post hoc Dunnett, Holm-Sidak or Uncorrected Fisher’s LSD 
test, or unpaired Student’s t-tests were used as appropriate to determine significant differences 
between groups. Results were deemed to be significant when p < 0.05. All data are presented as 












Quinacrine and Niclosamide promote neurite growth in SH-SY5Y cells and in primary 
midbrain dopaminergic neurons.  
We first showed that SH-SY5Y cells are a useful screening tool for small molecule drug 
discovery, using rhBMP2 as our positive control (Supplementary Fig. 1). Given that rhBMP2 is 
known to promote neurite growth in a number of neuronal cell types, including dopaminergic 
neurons [20, 26-28], and that Quinacrine and Niclosamide have been shown to upregulate BMP2 
expression in tendon tissue [21], we next tested the ability of both compounds to promote neurite 
growth as a readout of neurotrophic action at an individual cellular level. To do this, we performed 
a dose-response experiment in which SH-SY5Y cells were treated daily with increasing 
concentrations of either Quinacrine or Niclosamide (up to 10nM), or with 50ng/ml rhBMP2 as a 
positive control, for 72 h. Comparable results were found for both compounds whereby a 
concentration of 1 or 10nM Niclosamide (Fig. 1a, c) or Quinacrine (Fig. 1d, f) significantly 
increased neurite length relative to untreated controls, and to a similar extent to that induced by 
rhBMP2. These effects were not secondary to any effects of these drugs on cell number as we found 
that the numbers of cells in cultures treated with Niclosamide (Fig. 1b, c) or with Quinacrine (Fig. 
1e, f) were not significantly different from the controls. Collectively these data show that 
Quinacrine and Niclosamide promote neurite growth without any effects on cell number in SH-
SY5Y cell cultures.  
Although SH-SY5Y cells are a useful screening tool, they do not recapitulate all features 
of dopaminergic neurons. Therefore, we next performed a dose-response experiment in which we 
added increasing concentrations (0-10nM) of Quinacrine and Niclosamide to primary cultures of 
the E14 rat VM for 72 h and then analysed the neurite length and numbers of TH+ dopaminergic 
neurons in these cultures. We found that 0.1-10nM concentrations of both Niclosamide (Fig. 1g, 
k) or Quinacrine (Fig. 1i, l) induced a significant increase in neurite length in dopaminergic neurons 




Given that a 10nM concentration of Niclosamide or Quinacrine exerted the maximal increase in 
neurite length, we also examined TH+ cell survival at this concentration and found that both 
compounds did not increase the numbers of dopaminergic neurons in these cultures (Fig. 1h, j, k, 
l).  Collectively, these data show that Quinacrine and Niclosamide are well tolerated by 
dopaminergic neurons and are capable of eliciting phenotypic changes that are similar to those 
induced by the neurotrophic factor BMP2. Coupled with previous work showing that these drugs 
modulate BMP2 expression in tendon cells [21], collectively these data suggested that the effects 
of these drugs may be mediated through the canonical BMP-Smad signalling pathway.  
 
Quinacrine and Niclosamide activate BMP-Smad-dependent transcription in SH-SY5Y cells 
and increase phospho-Smad levels in primary dopaminergic neurons which are required for 
their neurite growth promoting effects. 
To test the hypothesis that Quinacrine or Niclosamide promote neurite growth through 
activation of the canonical BMP-Smad signalling, we next used a BMP-Smad reporter construct in 
which a BMP responsive element (BRE) drives the expression of GFP. Therefore, an increase in 
intracellular GFP expression is indicative of increased BMP-Smad-dependent transcription (Fig. 
2a). SH-SY5Y cells were transiently transfected with 250ng of the reporter plasmid. At 24 h post-
transfection, 10nM of Niclosamide or Quinacrine, or 50ng/ml rhBMP2 (as a positive control) was 
added to these cultures for a further 24 h. Treatment with 10nM Quinacrine or Niclosamide 
significantly increased GFP expression compared to untreated controls, to a similar extent as 
rhBMP2 treatment (Fig. 2b, c). These data show that Quinacrine and Niclosamide stimulate a BMP-
Smad-dependent transcriptional response in SH-SY5Y cells. 
Given that Quinacrine and Niclosamide activate BMP-Smad dependent transcription in 
SH-SY5Y cells, we next examined the relevance of this finding to primary cultures of 
dopaminergic neurons. We could not perform the same reporter assay as the transfection efficiency 




cultures, so we therefore used a modified approach. As phospho-Smad levels are indicative of 
BMP-Smad pathway activation, we immunocytochemically double-stained these cultures for TH 
and phospho-Smad1/5/8 which allowed us to analyse phospho-Smad1/5/8 levels specifically in 
TH+ dopaminergic neurons. We found that treatment with 10nM Quinacrine or 10nM Niclosamide 
for 24 h led to significant increases in phospho-Smad-1/5/8 levels in TH+ neurons, which was 
completely prevented by pre-treatment with the BMPR inhibitor, dorsomorphin (Fig. 2d, f). 
Similarly, Quinacrine- and Niclosamide-induced increases in neurite growth were prevented by 
pre-treatment with dorsomorphin (Fig. 2e, g). Collectively these data show that both Quinacrine 
and Niclosamide may mediate their phenotypic effects on midbrain dopaminergic neurons via the 
BMP-Smad signalling pathway. As BMPs have been shown to have neuroprotective effects on 
dopaminergic neurons [20, 26-29], this suggested that Quinacrine and Niclosamide may protect 
against dopaminergic degeneration, which is the pathological hallmark of PD. 
 
Quinacrine and Niclosamide protect dopaminergic neurons from MPP+ and 6-OHDA-
induced degeneration   
We next tested the hypothesis that Quinacrine and Niclosamide can protect dopaminergic 
neurons against degeneration induced by the neurotoxins, 6-OHDA and MPP+. To do this, primary 
cultures of E14 rat VM were treated with 10nM of Quinacrine or Niclosamide or Vehicle and 
cultured with or without 5µM 6-OHDA or MPP+, for 72 h. For Niclosamide, a two-way repeated 
measures ANOVA revealed a significant effect of both neurotoxins (F(1, 3) = 169.9, p = 0.0010) on 
neurite length, but no effect of Niclosamide (F(1.234, 3.701) = 4.449, p = 0.1072) and no interaction 
between Niclosamide and the neurotoxins (F(1.326, 3.978) = 0.5978, p = 0.5291). Furthermore, post-
hoc testing using an uncorrected Fisher’s LSD test revealed a significant reduction in neurite length 
of MPP+ (p = 0.0095) and 6-OHDA (p = 0.0018) versus the control (Fig. 3a, b), whereas no 
significant difference was found for MPP+ (p = 0.5321) and 6-OHDA (p = 0.1662) cultures co-




significant interaction between Quinacrine x Neurotoxins (F(1.44, 4.32) = 10.52, p = 0.0247) and both 
neurotoxins (F(1, 3) = 161.6, p = 0.0011) on neurite length, but no effect of Quinacrine alone (F(1.049, 
3.146) = 2.081, p = 0.2429). Furthermore, post-hoc testing using an uncorrected Fisher’s LSD test 
revealed a significant reduction in neurite length of MPP+ (p = 0.0008) and 6-OHDA (p = 0.0273) 
versus the control (Fig. 3c, e). While no significant difference was found for MPP+ (p = 0.7516) 
and 6-OHDA (p = 0.7713) cultures co-treated with Quinacrine.  
 We next sought to determine whether Quinacrine and Niclosamide can protect TH+ 
neurons against the neurotoxins MPP+ or 6-OHDA. Here, a two-way repeated measures ANOVA 
revealed a significant effect of the neurotoxins (F(1, 2.001) = 23.03, p = 0.0408) and the drug 
compounds (F(1.183, 2.366) = 21.16, p = 0.0316) on TH
+ neuron number. However there was no 
significant interaction between the drug compounds and the neurotoxins on TH+ cell number 
(F(1.293, 2.585) = 1.22, p = 0.3863). In addition, post-hoc testing using an uncorrected Fisher’s LSD 
test revealed a significant reduction in neurite length of MPP+ (p = 0.0097) and 6-OHDA (p = 
0.0263) versus the control (Fig. 3d). While no significant difference was found for MPP+ (p = 
0.1210) and 6-OHDA (p = 0.0.964) cultures co-treated with Niclosamide and no significant 
difference was found for MPP+ (p = 0.1167) and 6-OHDA (p = 0.3655) cultures co-treated with 
Quinacrine. Collectively, these data show that Quinacrine and Niclosamide can protect 
dopaminergic neurons against neurotoxin-induced degeneration. 
 
Quinacrine and Niclosamide protect dopaminergic neurons from AAV-α-Synuclein-induced 
axon degeneration  
As PD is characterised by the accumulation of α-synuclein, finally we sought to assess 
whether Quinacrine and Niclosamide could also protect dopaminergic neurons against α-synuclein-
induced degeneration in vitro. To do this we used an AAV-αSyn expression vector to express α-
synuclein in dopaminergic neurons in primary cultures of the E14 rat VM (Fig. 4a). Cultures were 




that had a detrimental effect on neurite length after 5 DIV, as a readout of neurodegeneration at an 
individual neuron level (Supplementary Fig. 2). AAV-αSyn with an MOI of 2.0×105 led to 
significant reductions in neurite length compared to the control AAV-GFP group.  
To assess whether treatment with Quinacrine or Niclosamide could protect against  -
synuclein-induced degeneration, Quinacrine or Niclosamide were administered using two different 
treatment paradigms in this model. In the first experiment, primary cultures of the E14 rat VM were 
transduced with either AAV-GFP or AAV-aSyn vectors and treated daily thereafter for 10 DIV in 
a concurrent treatment paradigm. A two-way ANOVA revealed a significant -synuclein x drug 
interaction on the numbers of TH+ dopaminergic neurons in these cultures (F(2, 10) = 5.388, p = 
0.0258). Post-hoc testing showed that  -synuclein resulted in a significant reduction in 
dopaminergic neuron number (p = 0.0015), that was not seen in cultures treated with Quinacrine 
(p = 0.4409) or Niclosamide (p = 0.4409) (Fig. 4b). We also examined dopaminergic neurite length, 
and found a significant effect of -synuclein (F(1, 4) = 9.656, p = 0.0360) and drug treatment (F(2, 8) 
= 21.37, p = 0.0006), with no significant interaction (F(2, 8) = 1.861, p = 0.2170). Post-hoc testing 
showed that -synuclein resulted in a significant reduction in dopaminergic neurite length (p = 
0.0315), that was not seen in cultures treated with Quinacrine (p = 0.4922) or Niclosamide (p = 
0.4922) (Fig. 4c).  These data show that concurrent treatment with Quinacrine or Niclosamide 
prevents -synuclein-induced reductions in dopaminergic neuron number and neurite length. 
Experiment 2 involved a delayed drug treatment paradigm. Primary cultures of the E14 rat 
VM were transduced with the AAV-GFP or AAV-aSyn vectors and left for 5 days. We then treated 
the cultures with Quinacrine or Niclosamide on day 5 and daily thereafter for an additional 5 DIV 
(10 days total). A two-way ANOVA showed a significant -synuclein x drug interaction on the 
numbers of TH+ dopaminergic neurons in these cultures (F(2, 10) = 6.420, p = 0.0161). Post-
hoc testing revealed that  -synuclein resulted in a significant reduction in dopaminergic neuron 
number (p = 0.0016), that was not seen in cultures treated with Quinacrine (p = 0.5259) or 




significant effect of -synuclein (F(1, 4) = 13.83, p = 0.0205) and drug treatment (F(2, 8) = 43.65, p < 
0.0001) with no significant interaction (F(2, 8) = 4.103, p = 0.0594) (Fig. 4e, f). Post-hoc testing 
showed that -synuclein resulted in a significant reduction in dopaminergic neurite length (p = 
0.0040), that was not seen in cultures treated with Quinacrine (p = 0.1278) or Niclosamide (p = 
0.4256). These data show that Quinacrine or Niclosamide, when given to neurons with an 




Neurotrophic factor therapy has attracted significant interest as a potential disease-modifying 
approach for the treatment of PD. However, the application of neurotrophic factors in a clinical setting 
currently requires direct administration to the brain via invasive surgery and has had limited success 
to date [13, 16, 17, 30].  BMP2 has been shown to have potent neurotrophic effects on dopaminergic 
neurons [20, 26, 28, 29]. Similar to other members of the BMP family, BMP2 exerts its effects via the 
canonical Smad signalling pathway [31, 32]. Therefore, the identification of small molecule 
compounds, that are known to cross the blood brain barrier and that could modulate the expression of 
BMP2 and/or BMP-Smad signalling in dopaminergic neurons, has potential therapeutic relevance for 
PD. The clinical application of such agents through non-surgical routes would be hugely advantageous 
from a safety perspective and allow wider application to patients. The FDA-approved small molecule 
drugs, Quinacrine and Niclosamide, have been shown to upregulate BMP2 expression in a dose-
dependent manner in a BMP2 reporter cell line and in human tendon-derived tissue [21]. Given the 
substantial evidence in support of BMP2 as a neurotrophic factor for dopaminergic neurons, this study 
investigated the effect of Quinacrine and Niclosamide on dopaminergic neurons using SH-SY5Y cells 
and primary cultures of the E14 rat VM.  
Firstly, SH-SY5Y cells were verified as an appropriate tool to screen drug compounds for 




shown to express high levels of BMP2’s receptors, BMPR1B and BMPR2, as well as Smad-1, -5 and 
-8, the effector molecules involved in initiating Smad signalling [33]. In addition, SH-SY5Y cells 
treated with rhBMP2 resulted in the activation of the Smad pathway, as shown by increased phospho-
Smad activation, as well as increased neurite length, and both of these effects were supressed by co-
treatment with dorsomorphin. This finding is supported by several studies showing that rhBMP2 
preferentially binds to BMPRI receptors [34-36] to activate canonical Smad signalling in C2C12 cells 
[37], SH-SY5Y cells [28, 38] and primary cultures of dopaminergic neurons [31]. In this study, both 
Quinacrine and Niclosamide were also found to promote neurite growth in SH-SY5Y cells and in 
cultured dopaminergic neurons, to the same extent as rhBMP2. Neither of these two compounds 
affected cell viability, rationalising their safe application to dopaminergic neurons. In contrast to this 
finding, exposure to 5µM Quinacrine induced the cell death of human tendon cells after 7 DIV [21], 
however the concentration of Quinacrine used on dopaminergic neurons in our study was significantly 
lower, at 10nM. In addition, Quinacrine and Niclosamide were also found to activate the Smad 
signalling pathway, as evidenced by upregulated Smad dependent transcription in SH-SY5Y cells, and 
increased phospho-Smad levels in cultured dopaminergic neurons. This effect on Smad signalling was 
not seen in human tendon cells [21], however in that study the cells were exposed to Quinacrine or 
Niclosamide for 2 h, in contrast to the 24 h timepoint used in the present study. Moreover, the effects 
of both Quinacrine and Niclosamide on neurite length and on phospho-Smad levels were blocked by 
dorsomorphin, showing that they were mediated through activation of the canonical Smad signalling 
pathway. This is consistent with findings showing that BMP neurotrophic effects were prevented by 
the use of dorsomorphin, which demonstrated their dependence on the canonical Smad signalling 
pathway to elicit neurotrophic action [28, 31].  
  We have recently shown that rhBMP2 promotes TH+ cell survival and neurite length, and that 
it protects against the selective dopaminergic neurotoxins MPP+ and 6-OHDA in primary cultures of 
the E14 VM [20]. In this study, Quinacrine and Niclosamide also demonstrated significant 




of this finding, Quinacrine has previously been shown to protect striatal dopamine levels in vivo 
against 6-OHDA and MPTP striatal lesioning in Wistar rats and C57BL mice, respectively [39]. In the 
MPTP study, adult male mice were administered one of four different doses of Quinacrine via 
intraperitoneal (i.p.) injection 30 min prior to the administration of 30mg/kg MPTP daily for 5 days. 
Mice were sacrificed on day 5 and striata were collected for HPLC analyses. For the 6-OHDA study, 
Wistar rats were administered one of four different doses of Quinacrine via i.p. injection 30 min prior 
to a unilaterally 6-OHDA lesion to the right striatum and were treated daily thereafter for 4 days. On 
day 5, animals were sacrificed and striata were collected for HPLC analyses. In both studies, they 
found MPTP and 6-OHDA significantly reduced striatal DA and glutathione (GSH), which was 
attenuated by co-treatment with Quinacrine in a dose-dependent fashion [39]. In addition, Niclosamide 
fully prevented the degeneration induced by MPP+ and 6-OHDA on neurite length, and was protective 
against the effect of MPP+, but not 6-OHDA, on TH+ cell survival. These findings demonstrate that 
Quinacrine and Niclosamide can protect midbrain dopaminergic neurons against neurotoxin-induced 
dopaminergic degeneration, which is the clinical hallmark of PD. 
We have previously shown that rhBMP2 is protective against axon degeneration induced by 
the overexpression of both wild-type and mutant A53T α-synuclein plasmids in E14 VM cultures [20]. 
Therefore, in this experiment E14 VM cultures were transduced with an AAV-αSyn vector at an MOI 
that induced axon degeneration in dopaminergic neurons. The approach to this study was two-fold: to 
investigate if Quinacrine and Niclosamide could protect dopaminergic nerve cells and their terminals 
from α-synuclein, and if so, if these compounds could restore dopaminergic nerve terminals after 
degeneration had already occurred. Concurrent treatment with Quinacrine or Niclosamide at the time 
of AAV-αSyn transduction protected TH+ neurons against α-synuclein-induced axon degeneration and 
promoted dopaminergic cell survival. In addition, treatment with Quinacrine or Niclosamide 5 days 
after the AAV-αSyn infection, when degeneration had already occurred, also protected TH+ neurons 
against α-synuclein-induced axon degeneration and promoted dopaminergic cell survival. These 




event that precedes symptom onset and initiates nigrostriatal neuron loss in PD [40, 41]. Thus, the 
advent of new therapeutics that can substantially restore dopaminergic nerve terminals within the 
nigrostriatal pathway is important.   
In addition to its effects on BMP signalling in dopaminergic neurons, it is worth noting that 
Quinacrine has also been shown to be a potent non-selective inhibitor of phospholipase A2 (PLA2) [39, 
42]. PLA2 is an important enzyme in the inflammatory response, and within the brain, PLA2 regulates 
the conversion of arachidonic acid into proinflammatory mediators and its reabsorption into the 
membrane [43]. When PLA2 activity becomes disrupted, abnormally high numbers of 
proinflammatory mediators are produced, resulting in oxidative stress and neuroinflammation 
analogous to neurological diseases, such as PD [43]. PLA2 is also known to play a role in regulating 
the synaptic release of dopamine within the adrenal medulla [44]. A study demonstrated that rats that 
had received a unilateral intranigral injection of PLA2 displayed significantly increased apomorphine-
induced rotational behaviour, suggesting that PLA2 can cause severe inhibition of dopamine release 
within the nigrostriatal pathway [45]. In support of this, another study observed that mice deficient in 
group IV cytosolic PLA2 were resistant to the degenerative effects of the dopaminergic neurotoxin 
MPTP [46]. These studies support the hypothesis that inhibitors of PLA2, like Quinacrine, could be a 
promising lead for the treatment of neurological disorders.  Interestingly, it has been shown that TGF-
β signalling in mesangial cells, leading to the activation of Smad proteins, attenuates PLA2 signalling 
[47]. Consequently, further work is needed to clarify whether a relationship exists between BMP-Smad 
signalling and PLA2 activity in dopaminergic neurons, which may further elucidate the mechanism of 
action of Quinacrine. 
Similarly, Niclosamide is also known to modulate several cell signalling cascades, including 
Wnt/β-catenin, mTOR, JAK/STAT3 and NF-κB, and can cause mitochondrial depolarisation through 
the uncoupling of oxidative phosphorylation [22, 48, 49]. This is interesting as PINK1, a mitochondrial 
serine/threonine-protein kinase, regulates mitochondrial homeostasis and is activated by mitochondrial 




recessive forms of early onset PD [51]. Niclosamide treatment has also been shown to indirectly 
activate endogenous PINK1 signalling in cultured cortical neurons [52]. These findings suggest a 
possible therapeutic role for Niclosamide to slow the progression of PD neuropathology through the 
activation of PINK1, as well as BMP signalling. 
In summary, this study has shown that the FDA-approved drugs Quinacrine and Niclosamide 
elicit positive phenotypic changes in both SH-SY5Y cells and primary cultures of dopaminergic 
neurons. Specifically, these drugs confer neurotrophic effects on SH-SY5Y cells and cultured 
dopaminergic neurons by stimulating the canonical BMP-Smad signalling pathway. Furthermore, 
Quinacrine and Niclosamide have been shown to be protective against MPP+- and 6-OHDA-induced 
dopaminergic degeneration and can protect and restore dopaminergic axon degeneration caused by 
AAV-αSyn. Further work is now needed to examine the effects of Quinacrine and Niclosamide in in 
vivo models of PD, such as the AAV-αSyn rat model, and to further explore the mechanism of action 
of these compounds. This study adds considerable evidence to the potential use of these small molecule 
drugs to protect dopaminergic neurons and justifies their further investigation as potential therapeutic 















Figures and Figure Legends  
 
Fig. 1. Quinacrine and Niclosamide promote neurite growth in SH-SY5Y cells and in primary 
midbrain dopaminergic neurons. (a) Total neurite length, (b) total cell number and (c) 
representative photomicrographs of SH-SY5Y cells following treatment with Niclosamide at the 
concentrations indicated for 72 h. (d) Total neurite length, (e) total cell number and (f) 
representative photomicrographs of SH-SY5Y cells following treatment with Quinacrine at the 
concentrations indicated for 72 h. Scale bar = 50µM. All data are presented as mean ± SEM from 
at least three experiments. (*p < 0.05, **p < 0.01, ***p < 0.001 vs. control or as indicated. One-




as a percentage of the untreated control following treatment with Niclosamide at the concentrations 
indicated for 72 h. (i) Total neurite length and (j) numbers of TH+ neurons as a percentage of the 
untreated control following treatment with Quinacrine at the concentrations indicated for 72 h. (k, 
l) Representative photomicrographs of E14 VM cultures following 10nM treatment of (k) 
Niclosamide and (l) Quinacrine for 72 h. Scale bar = 50µM. All data are presented as mean ± SEM 
from at least three experiments. (*p < 0.05, **p < 0.01, ***p < 0.001 vs. control. One-way repeated 








Fig. 2. Quinacrine and Niclosamide activate BMP-Smad-dependent transcription in SH-
SY5Y cells and increase phospho-Smad levels in primary dopaminergic neurons which are 
required for their neurite growth-promoting effects. (a) Schema showing SBE-GFP reporter 
system. (b) SBE-driven GFP expression expressed as a percentage of that in vehicle cells and (c) 
representative photomicrographs of SH-SY5Y cells following 24 h treatment of 10nM Niclosamide 
or Quinacrine or 50ng/ml rhBMP2. Scale bar = 10µM. (d) Phospho-Smad activation and (e, f) 
representative photomicrographs of E14 VM cultures, immunocytochemically stained for (e) TH 
and (f) phospho-Smad, following 24 h treatment of 10nM Niclosamide or Quinacrine with or 
without 1µg/ml dorsomorphin. (g) Total neurite length of TH+ neurons in E14 VM cultures 
following 24 h treatment of 10nM Niclosamide or Quinacrine with or without 1µg/ml 
dorsomorphin. Scale bar = 50µM. All data are presented as mean ± SEM from at least three 
experiments. (*p < 0.05, **p < 0.01 vs. control or as indicated. One-way repeated measures 







Fig. 3. Quinacrine and Niclosamide protect dopaminergic neurons from MPP+ and 6-OHDA-
induced degeneration. (a) Representative photomicrographs and (b) total neurite length of E14 
VM cultures after 72 h treatment with 10nM Niclosamide with or without 5µM MPP+ or 6-OHDA. 
(c) Total neurite length and (e) representative photomicrographs of E14 VM cultures after 72 h 
treatment with 10nM Quinacrine with or without 5µM MPP+ or 6-OHDA. (d) Numbers of TH+ 
neurons as a percentage of the control in E14 VM cultures after 72 h treatment with 10nM 
Quinacrine or Niclosamide with or without 5µM MPP+ or 6-OHDA. Scale bar = 50µM. All data 
are presented as mean ± SEM from at least three experiments. (* p < 0.05, ** p < 0.01, *** p < 






Fig. 4. Quinacrine and Niclosamide protect midbrain dopaminergic neurons against α-




after transduction with AAV2/6-GFP or AAV2/6-α-Synuclein at an MOI of 2 × 105 and 
immunocytochemically stained for TH and α-Synuclein, and counterstained with DAPI after 5 
DIV. (b) Number and (c) neurite length of TH+ neurons in E14 VM cultures transduced with AAV-
GFP or AAV-α-Synuclein and cultured with or without 10nM Quinacrine or Niclosamide daily for 
10 DIV. (d) DA neuron number, (e) DA neurite length and (f) representative photomicrographs of 
E14 TH+ neurons infected with AAV-GFP or AAV-α-Synuclein and cultured with or without 10nM 
Quinacrine or Niclosamide after 5 DIV daily up to 10 DIV. Scale bar = 50µm. All data are 
presented as mean ± SEM from at least three experiments. (* p < 0.05, ** p < 0.01 vs. control; 





















Suplementary Figures and Figure Legends 
 
Fig. 1. SH-SY5Y cells as a tool to study drugs affecting BMP-Smad signalling.  Representative 
photomicrographs showing immunocytochemical staining for (a) BMPR1B, (b) BMPR2 and (c) 
Smad1/5/8 expression in SH-SY5Y cells. (d) Representative photomicrographs of 
immunocytochemical staining of p-Smad1/5/8 and (e) intensity of p-Smad1/5/8 as measured using 
ELISA in SH-SY5Y cells after treatment with 50ng/ml rhBMP2 with and without 1µg/ml 
dorsomorphin for 2 h. (f) Total neurite length and (h) representative photomicrographs of SH-
SY5Y cells after treatment with 10, 50 or 200ng/ml rhBMP2 for 24 h. (g) Total neurite length and 
(i) representative photomicrographs of SH-SY5Y cells after treatment with 1µg/ml dorsomorphin 




three experiments. (*p < 0.05, **p < 0.01, ***p < 0.001 vs. control; +++p < 0.001 vs rhBMP2. One-
way ANOVA with Tukey’s post-hoc test). 
 
Fig. 2. AAV-α-synuclein affects neurite length of cultured dopaminergic neurons in a 
concentration-dependent manner.  (a) Graph and (b) representative photomicrographs of TH+ 
neurons transduced with AAV2/6-GFP or AAV2/6-α-synuclein at the MOI’s indicated for 5 DIV. 
Scale bar = 50µm. All data are presented as mean ± SEM from at least three experiments. (**p < 0.01 
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